Physicians and researchers from the United States and around the world will present groundbreaking research from late-breaking clinical trials, follow-up data from major randomized trials and registries, and first-in-man experiences with novel devices or drugs. A multidisciplinary, international panel of expert physicians, scientists, and regulators will ask questions and shed light on the lasting impact of the research results presented.
A limited number of abstracts will be accepted for presentation; please read the submission guidelines carefully before submitting your abstract for consideration. Accepted late-breaking clinical trials will be presented during Global Theater on Tuesday and Wednesday, November 5 and 6. Presentations will be nine minutes each and will be followed by a Q&A with questions posed by an expert panel and the audience. VIVA will work with media by providing a press room on-site, press conferences, and press releases featuring the late-breaking clinical trials prior to and during VIVA.
Abstract submission deadline is August 22, 2019.
Research must be original and may not have been presented prior to presentation at VIVA. Abstracts must be submitted electronically via the official VIVA abstract submission website. Paper submissions will not be accepted.
Abstract submissions should address areas of endovascular medicine and report the results of:
Abstract submissions must include:
The following information must be provided upon submission:
Submitted abstracts will be reviewed after the submission deadline. Abstracts will be evaluated and scored based on the following criteria:
Notification of acceptance or rejection will be sent the week of September 9, 2019. The acceptance letter will be followed up with an additional letter that will include complete information regarding presentation of abstracts, including date and time of presentation and press conference. For abstracts that are selected, presenters who are not VIVA faculty will be given complimentary registration to VIVA, but will be responsible for their own travel and accommodations.
If you have questions please contact Rachel DeLuna via e-mail: firstname.lastname@example.org.
VIVA embargoes information presented as a late-breaking clinical trial from becoming public until after the commencement of the Late-Breaking Clinical Trial Session in the Global Theater as listed in the program agenda (all embargo times will be listed in Pacific Daylight Time). No publication, exhibitor, or affiliated company may disseminate information until after the commencement of the Late-Breaking Clinical Trial session in which it is presented.Click Here to Submit